This oncology drug snapshot takes a look at axitinib (Inlyta) for the treatment of advanced renal cell carcinoma (RCC) after failure of one prior systemic therapy.
FDA Deems Mesoblast’s Data on Remestemcel-L Cell Therapy Sufficient for BLA Submission in Pediatric SR-aGVHD
The company noted that it plans to submit the BLA in the second quarter of 2024.
FDA Approves First CAR T-Cell Therapy for CLL and SLL
In March 2024, the FDA approved the CAR T-cell therapy lisocabtagene maraleucel (Breyanzi) as a treatment for relapsed or resistant chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL).
AOC Therapy Yields Strength Improvements in Myotonic Dystrophy
Avidity is currently enrolling in the phase 3 HARBOR trial, which it expects to initiate in the second quarter of 2024.
Tackling Challenges in CAR-T Fertility Research
John Ligon, MD, an assistant professor in the department of pediatrics at the University of Florida College of Medicine, discussed his view of the main priorities for research in this area.
CGTLive®’s Weekly Rewind – March 22, 2024
Review top news and interview highlights from the week ending March 22, 2024.
BlueRock Therapeutics' Parkinson Disease Cell Therapy Bemdaneprocel Shows Safety and Efficacy at 18 Months Posttreatment
Bemdaneprocel remained well-tolerated and no major safety issues had occurred in the treated patients.